Company intelligence / Profile preview

Atrix Laboratories

Fort Collins, Colorado, United States

Ownership: Private
Employees: ~98
Development stage: Other

Overview

Atrix Laboratories developed the Atridox gel for treating periodontal disease (commercially available). Their prostate cancer therapy reached late-stage clinical development. Acne medication was in Phase 2 at the time of reporting. Their drug delivery platforms achieved important industry partnerships (notably with Pfizer).

Therapeutic areas: OncologyNeurologyDermatologyOther
Modalities: Small moleculeGel-based drug delivery therapy
Industry: Biotech

Partnerships

Pfizer (major nonexclusive R&D/drug delivery platform partnership)PharmaScience Inc. (marketing/distribution deal for dental products in Canada)Genmedix (Israel, distribution of dental products including Atridox)CollaGenex Pharmaceuticals (US marketing/distribution for Periostat in conjunction with Atridox in periodontitis)

Beyond the preview

Go deeper on Atrix Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atrix Laboratories.

Explore the full profile